森萱医药(830946) - 2022 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2022 reached ¥182,603,038.82, representing a year-on-year increase of 30.63% compared to ¥139,788,669.27 in Q1 2021[14] - Net profit attributable to shareholders for Q1 2022 was ¥49,972,953.24, up 23.47% from ¥40,474,012.63 in the same period last year[14] - The net cash flow from operating activities increased by 57.04% to ¥41,670,594.01, compared to ¥26,534,388.23 in Q1 2021[14] - Basic earnings per share for Q1 2022 were ¥0.1171, reflecting a 23.52% increase from ¥0.0948 in Q1 2021[14] - The total sales revenue for the period was ¥114,578,823.47, compared to ¥114,860,708.39 in the previous period, indicating a slight decrease[20] - The company reported a net increase in cash and cash equivalents of ¥53,571,634.59, up from ¥52,076,721.26 in the previous period[20] - Total operating revenue for the period was 120,725,024.05, an increase from 89,254,377.61 in the previous period, reflecting a growth of approximately 35.3%[80] - Net profit for the period reached 53,340,658.13, compared to 43,454,614.55 in the same period last year, representing an increase of about 22.5%[81] Assets and Liabilities - Total assets as of March 31, 2022, were ¥1,239,285,533.57, a 3.03% increase from ¥1,202,864,513.38 at the end of 2021[14] - The net assets attributable to shareholders increased by 5.06% to ¥1,052,935,234.63 from ¥1,002,268,468.65 at the end of the previous year[14] - The company's debt-to-asset ratio decreased to 9.55% from 11.33% year-on-year, indicating improved financial stability[14] - Total liabilities decreased to ¥118,355,182.45 from ¥136,233,225.53, indicating a reduction of approximately 13.1%[73] - Current liabilities totaled ¥112,854,794.80, down from ¥130,248,976.17, showing a decline of around 13.3%[72] - Non-current liabilities were reported at ¥5,500,387.65, a slight decrease from ¥5,984,249.36, representing a reduction of about 8.0%[73] - Shareholders' equity increased to ¥1,120,930,351.12 from ¥1,066,631,287.85, marking a growth of approximately 5.1%[73] Cash Flow - The company's cash and cash equivalents at the end of the period amounted to ¥358,923,697.42, an increase from ¥359,406,262.86 at the beginning of the period[20] - The total cash paid for taxes during the period was ¥12,418,704.66, slightly down from ¥12,483,047.84 in the previous period[20] - Operating cash flow for Q1 2022 was CNY 41,670,594.01, a 57% increase from CNY 26,534,388.23 in Q1 2021[85] - Cash and cash equivalents at the end of Q1 2022 totaled CNY 313,683,749.03, down from CNY 359,406,262.86 at the end of Q1 2021[86] - The company experienced a net decrease in cash and cash equivalents of CNY 15,624,365.24 in Q1 2022, compared to an increase of CNY 8,656,465.11 in Q1 2021[88] Shareholder Commitments and Governance - The commitments made during the company's listing are currently being fulfilled by the board members and major shareholders[31] - The commitments related to major asset restructuring have been completed, while some are still in progress, including those concerning independence and liability for losses[32] - The company has a plan to stabilize its stock price for three years post-listing, which includes specific measures to be taken if the stock price falls below the audited net asset value per share[34] - The company can repurchase shares if the stock price remains below the audited net asset value for ten consecutive trading days after implementing profit distribution or capital reserve conversion[37] - The controlling shareholder is required to propose a plan to increase their shareholding if the stock price remains low after the repurchase[38] - The company will require new directors and senior management to sign commitments to uphold stock price stabilization measures[41] - The company’s controlling shareholder has committed not to interfere with the company's management or harm its interests[43] Profit Distribution Policy - The company has developed a profit distribution policy to ensure stable and reasonable returns for investors, considering factors like profitability and cash flow[45] - The company will implement a continuous and stable profit distribution policy, with annual profit distribution plans proposed by the board of directors[46] - The company adopts a cash, stock, or a combination of both methods for profit distribution, prioritizing cash distribution[48] - The company plans to distribute at least 10% of the annual distributable profit in cash when conditions are met, and at least 30% of the average annual distributable profit over any three consecutive years[49] - The company aims to maintain a cash dividend ratio of at least 80% for mature stages without significant capital expenditure, and at least 40% with significant capital expenditure[49] Compliance and Legal Responsibilities - The controlling shareholder guarantees the authenticity and completeness of the public offering application documents, accepting legal responsibility for any inaccuracies[56] - All directors, supervisors, and senior management confirm the accuracy of the public offering application documents and accept legal responsibility[57] - The underwriter and auditing firm have committed to the accuracy of the public offering documents, agreeing to compensate investors for any losses caused by inaccuracies[57] - The company will publicly explain any failure to fulfill commitments and apologize to shareholders if such failures occur[60] - The company will ensure compliance with legal regulations regarding shareholding and will bear responsibility for any violations[56]